Low level of plasma DNase is associated with worse clinical outcome in testicular germ cell tumor patients and exogeneous DNase I improves cisplatin treatment efficacy
Our data confirm the association between low plasma DNase activity and worse overall survival for the first time in GCT patients. This study further validated the prognostic value of total ecDNA in GCT patients. More importantly, our preclinical data substantiated beneficial effect of Pulmozyme combination with cisplatin treatment to improve the therapeutic outcome in refractory disease.
Authors
- Kalavska Katarina (ORCID: https://orcid.org/0000-0003-2897-1477)
- Cierna Zuzana
- Sestakova Zuzana
- Kucerova Lucia
- Chovanec Miroslav
- Michal Mego (ORCID: https://orcid.org/0000-0002-6511-6827)
- Peter Celec (ORCID: https://orcid.org/0000-0001-5883-3580)
- P. Michal
- Vlkova Barbora
- Udvorkova Natalia
Institutions
- University of Trnava (SK)
- Cancer Research Institute of the Slovak Academy of Sciences (SK)
- Biomedical Research Center of the Slovak Academy of Sciences (SK)
- Comenius University Bratislava (SK)
Publication Details
- Journal
- PLoS ONE
- Published
- 2025-12-04
- DOI
- https://doi.org/10.1371/journal.pone.0336190
- Primary Topic
- Testicular diseases and treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00